Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention describes the use of rho GTPase function inhibitors as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention describes methods that employ Rho GTPase function inhibitors to treat conditions that result from the abnormally low
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention relates to the use of agents that disrupt actin cytoskeletal organization as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention relates to methods that employ agents that disrupt actin cytoskeletal organization to treat
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO.
BACKGROUND OF THE INVENTION
Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia. This
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO substitute.
BACKGROUND OF THE INVENTION
Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention describes the new use of HMG-CoA reductase inhibitors as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention describes methods that employ HMG-CoA reductase inhibitors to treat conditions that result from the abnormally low
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of
La base de dades d’herbes medicinals més completa avalada per la ciència
Funciona en 55 idiomes
Cures a base d'herbes recolzades per la ciència
Reconeixement d’herbes per imatge
Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
Llegiu publicacions científiques relacionades amb la vostra cerca
Cerqueu herbes medicinals pels seus efectes
Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza. * Tota la informació es basa en investigacions científiques publicades